James Miller
Concepts (326)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 44 | 2020 | 2221 | 2.910 |
Why?
| Smoking | 20 | 2019 | 1457 | 1.350 |
Why?
| Bronchi | 13 | 2018 | 241 | 1.310 |
Why?
| Carcinoma in Situ | 5 | 2019 | 43 | 1.190 |
Why?
| Carcinogens | 4 | 2012 | 106 | 0.820 |
Why?
| Carcinoma, Squamous Cell | 10 | 2018 | 610 | 0.810 |
Why?
| Chemoprevention | 3 | 2019 | 88 | 0.780 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2012 | 86 | 0.770 |
Why?
| Lung | 16 | 2020 | 3588 | 0.670 |
Why?
| Carcinoma, Small Cell | 7 | 2008 | 158 | 0.540 |
Why?
| Bronchopulmonary Dysplasia | 2 | 2019 | 328 | 0.520 |
Why?
| Urethane | 3 | 2012 | 41 | 0.520 |
Why?
| Bronchoscopy | 9 | 2019 | 244 | 0.500 |
Why?
| Sputum | 8 | 2019 | 289 | 0.500 |
Why?
| Pulmonary Alveoli | 4 | 2012 | 373 | 0.490 |
Why?
| Iloprost | 2 | 2012 | 46 | 0.490 |
Why?
| Hyperplasia | 7 | 2011 | 169 | 0.490 |
Why?
| Precancerous Conditions | 7 | 2020 | 156 | 0.470 |
Why?
| Neprilysin | 3 | 1998 | 47 | 0.450 |
Why?
| Biomarkers, Tumor | 7 | 2015 | 1053 | 0.440 |
Why?
| Piperidines | 2 | 2012 | 168 | 0.430 |
Why?
| Quinazolines | 2 | 2012 | 244 | 0.420 |
Why?
| Antineoplastic Agents | 4 | 2013 | 1941 | 0.420 |
Why?
| Biopsy | 11 | 2019 | 1056 | 0.410 |
Why?
| DNA Copy Number Variations | 1 | 2011 | 158 | 0.370 |
Why?
| Bombesin | 5 | 1998 | 14 | 0.370 |
Why?
| Genetic Markers | 1 | 2011 | 338 | 0.370 |
Why?
| Amidohydrolases | 3 | 1998 | 29 | 0.350 |
Why?
| Carcinoma, Non-Small-Cell Lung | 7 | 2013 | 974 | 0.350 |
Why?
| Neurosecretory Systems | 4 | 2004 | 32 | 0.340 |
Why?
| Tocopherols | 1 | 2009 | 20 | 0.340 |
Why?
| Isotretinoin | 1 | 2009 | 22 | 0.340 |
Why?
| Ki-67 Antigen | 3 | 2015 | 105 | 0.340 |
Why?
| Vasodilator Agents | 1 | 2011 | 311 | 0.340 |
Why?
| Mass Screening | 3 | 2008 | 1034 | 0.340 |
Why?
| ErbB Receptors | 1 | 2012 | 569 | 0.330 |
Why?
| Membrane Proteins | 2 | 2008 | 1040 | 0.320 |
Why?
| Neovascularization, Pathologic | 6 | 2015 | 286 | 0.310 |
Why?
| Pulmonary Disease, Chronic Obstructive | 4 | 2018 | 1114 | 0.290 |
Why?
| Respiratory Mucosa | 2 | 2008 | 253 | 0.290 |
Why?
| Adenocarcinoma | 6 | 2012 | 793 | 0.270 |
Why?
| Hypoxia | 1 | 2012 | 950 | 0.270 |
Why?
| Middle Aged | 28 | 2019 | 27170 | 0.240 |
Why?
| Chromosomes, Human, Pair 3 | 4 | 2000 | 50 | 0.240 |
Why?
| Aged | 25 | 2019 | 19356 | 0.240 |
Why?
| Chromosome Aberrations | 4 | 2013 | 135 | 0.230 |
Why?
| Carcinoma, Bronchogenic | 2 | 2002 | 17 | 0.230 |
Why?
| Tomography, Spiral Computed | 1 | 2002 | 24 | 0.220 |
Why?
| Humans | 53 | 2020 | 117047 | 0.210 |
Why?
| Female | 33 | 2019 | 60630 | 0.210 |
Why?
| Sensitivity and Specificity | 10 | 2010 | 1740 | 0.200 |
Why?
| Double-Blind Method | 2 | 2019 | 1670 | 0.200 |
Why?
| Smokers | 2 | 2019 | 148 | 0.200 |
Why?
| Lung Diseases | 5 | 2015 | 693 | 0.190 |
Why?
| Placebos | 2 | 2019 | 198 | 0.190 |
Why?
| Small Cell Lung Carcinoma | 2 | 2012 | 83 | 0.190 |
Why?
| Male | 30 | 2019 | 56660 | 0.190 |
Why?
| Tomography, X-Ray Computed | 2 | 2020 | 2403 | 0.190 |
Why?
| Tumor Cells, Cultured | 6 | 1998 | 860 | 0.170 |
Why?
| Neuropeptides | 4 | 1998 | 66 | 0.170 |
Why?
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 108 | 0.170 |
Why?
| Remission Induction | 1 | 2019 | 243 | 0.160 |
Why?
| Peptides | 3 | 1996 | 868 | 0.160 |
Why?
| In Situ Hybridization, Fluorescence | 6 | 2010 | 310 | 0.160 |
Why?
| Blotting, Western | 4 | 2012 | 1172 | 0.150 |
Why?
| Lung Diseases, Obstructive | 1 | 1997 | 40 | 0.150 |
Why?
| Genes, p53 | 1 | 1997 | 64 | 0.150 |
Why?
| Antibodies, Monoclonal | 3 | 2010 | 1271 | 0.150 |
Why?
| Proteomics | 2 | 2015 | 844 | 0.150 |
Why?
| Point Mutation | 1 | 1997 | 225 | 0.140 |
Why?
| Immunohistochemistry | 8 | 2015 | 1657 | 0.140 |
Why?
| Radiation Injuries, Experimental | 1 | 1996 | 24 | 0.140 |
Why?
| Bradykinin | 1 | 1996 | 46 | 0.130 |
Why?
| Mice | 10 | 2012 | 15308 | 0.130 |
Why?
| Endopeptidases | 1 | 1996 | 71 | 0.130 |
Why?
| Chromosomal Instability | 2 | 2013 | 18 | 0.130 |
Why?
| Animals | 13 | 2013 | 32736 | 0.130 |
Why?
| Smoking Cessation | 1 | 2019 | 357 | 0.130 |
Why?
| Hyperoxia | 1 | 1996 | 93 | 0.130 |
Why?
| Multiple Pulmonary Nodules | 1 | 2015 | 26 | 0.120 |
Why?
| Risk Factors | 5 | 2019 | 8873 | 0.120 |
Why?
| Aged, 80 and over | 8 | 2015 | 6453 | 0.120 |
Why?
| Antigens | 1 | 1996 | 319 | 0.120 |
Why?
| Methylcholanthrene | 2 | 2012 | 18 | 0.120 |
Why?
| Gene Expression | 3 | 1998 | 1466 | 0.120 |
Why?
| Mice, Transgenic | 5 | 2009 | 1993 | 0.120 |
Why?
| Butylated Hydroxytoluene | 2 | 2012 | 32 | 0.120 |
Why?
| Mutation | 4 | 2000 | 3420 | 0.120 |
Why?
| Algorithms | 3 | 2020 | 1505 | 0.120 |
Why?
| Microarray Analysis | 1 | 2013 | 119 | 0.110 |
Why?
| Stem Cells | 1 | 2018 | 547 | 0.110 |
Why?
| Epithelium | 4 | 2018 | 302 | 0.110 |
Why?
| Intramolecular Oxidoreductases | 2 | 2004 | 58 | 0.110 |
Why?
| Epithelial Cells | 3 | 2007 | 940 | 0.110 |
Why?
| Biological Products | 1 | 1996 | 176 | 0.110 |
Why?
| Carcinoma, Large Cell | 1 | 2012 | 14 | 0.110 |
Why?
| Cytochrome P-450 Enzyme System | 2 | 2004 | 110 | 0.110 |
Why?
| Risk | 5 | 2012 | 842 | 0.110 |
Why?
| Receptors, Bombesin | 1 | 2012 | 3 | 0.100 |
Why?
| Bronchoalveolar Lavage Fluid | 3 | 2002 | 600 | 0.100 |
Why?
| Case-Control Studies | 8 | 2012 | 3099 | 0.100 |
Why?
| Volatile Organic Compounds | 1 | 2012 | 58 | 0.100 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 194 | 0.100 |
Why?
| Cell Division | 4 | 2000 | 767 | 0.100 |
Why?
| Veterans | 1 | 2002 | 1231 | 0.100 |
Why?
| Sleep Apnea Syndromes | 1 | 2012 | 80 | 0.100 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 115 | 0.100 |
Why?
| Dose-Response Relationship, Drug | 2 | 2010 | 1889 | 0.100 |
Why?
| Chromosomes, Human, Pair 15 | 1 | 2011 | 53 | 0.100 |
Why?
| Eosinophilic Granuloma | 1 | 1990 | 3 | 0.090 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2012 | 171 | 0.090 |
Why?
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2012 | 219 | 0.090 |
Why?
| Adult | 16 | 2018 | 31003 | 0.090 |
Why?
| Predictive Value of Tests | 4 | 2009 | 1824 | 0.090 |
Why?
| Antioxidants | 2 | 2012 | 554 | 0.090 |
Why?
| Disease Progression | 5 | 2018 | 2467 | 0.090 |
Why?
| Calcium | 1 | 1996 | 1125 | 0.090 |
Why?
| Proteins | 1 | 1996 | 930 | 0.090 |
Why?
| Cell Line | 5 | 2013 | 2670 | 0.090 |
Why?
| Plants, Toxic | 1 | 1989 | 28 | 0.090 |
Why?
| Somatomedins | 1 | 2009 | 27 | 0.090 |
Why?
| Genome-Wide Association Study | 2 | 2013 | 1314 | 0.090 |
Why?
| Cell Proliferation | 2 | 2018 | 2236 | 0.090 |
Why?
| Intracellular Signaling Peptides and Proteins | 2 | 2011 | 399 | 0.090 |
Why?
| Chromosome Deletion | 1 | 1989 | 94 | 0.080 |
Why?
| Bronchial Neoplasms | 1 | 2009 | 14 | 0.080 |
Why?
| Neoplasms, Glandular and Epithelial | 1 | 2009 | 40 | 0.080 |
Why?
| Neoplasm Invasiveness | 4 | 2015 | 453 | 0.080 |
Why?
| GPI-Linked Proteins | 1 | 2008 | 56 | 0.080 |
Why?
| Respiratory System | 1 | 1989 | 141 | 0.080 |
Why?
| Airway Obstruction | 3 | 2009 | 165 | 0.080 |
Why?
| Fluorescence | 3 | 2009 | 157 | 0.080 |
Why?
| Inflammation | 1 | 2018 | 2515 | 0.080 |
Why?
| Alkaline Phosphatase | 1 | 2008 | 152 | 0.080 |
Why?
| Spectral Karyotyping | 1 | 2007 | 5 | 0.080 |
Why?
| Polymorphism, Genetic | 1 | 2011 | 629 | 0.080 |
Why?
| Fibroblasts | 3 | 1998 | 839 | 0.070 |
Why?
| Molecular Targeted Therapy | 1 | 2010 | 354 | 0.070 |
Why?
| Isoenzymes | 1 | 2008 | 293 | 0.070 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2008 | 232 | 0.070 |
Why?
| Cell Transformation, Neoplastic | 1 | 2009 | 311 | 0.070 |
Why?
| Pulmonary Surfactants | 2 | 1999 | 98 | 0.070 |
Why?
| Exons | 2 | 1998 | 302 | 0.070 |
Why?
| Molecular Sequence Data | 5 | 1998 | 2817 | 0.070 |
Why?
| Early Detection of Cancer | 1 | 2010 | 356 | 0.070 |
Why?
| Follow-Up Studies | 2 | 2015 | 4507 | 0.070 |
Why?
| MicroRNAs | 1 | 2012 | 627 | 0.070 |
Why?
| Biomarkers | 3 | 2010 | 3549 | 0.070 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2013 | 2038 | 0.070 |
Why?
| ROC Curve | 3 | 2015 | 460 | 0.070 |
Why?
| Enzyme-Linked Immunosorbent Assay | 3 | 2005 | 798 | 0.070 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2008 | 391 | 0.060 |
Why?
| Recombinant Proteins | 3 | 1998 | 1258 | 0.060 |
Why?
| RNA, Messenger | 3 | 1998 | 2632 | 0.060 |
Why?
| Polymerase Chain Reaction | 3 | 1998 | 1001 | 0.060 |
Why?
| Protein Kinase Inhibitors | 1 | 2010 | 803 | 0.060 |
Why?
| Growth Hormone-Releasing Hormone | 1 | 2004 | 27 | 0.060 |
Why?
| Cytokines | 1 | 2012 | 1852 | 0.060 |
Why?
| Acromegaly | 1 | 2004 | 15 | 0.060 |
Why?
| Rats | 4 | 2004 | 5172 | 0.060 |
Why?
| Neoplasm Recurrence, Local | 1 | 2009 | 878 | 0.060 |
Why?
| Adrenocorticotropic Hormone | 1 | 2004 | 151 | 0.060 |
Why?
| Cross-Sectional Studies | 2 | 2018 | 4510 | 0.060 |
Why?
| Smoke | 1 | 2004 | 135 | 0.050 |
Why?
| Base Sequence | 3 | 1998 | 2123 | 0.050 |
Why?
| Solitary Pulmonary Nodule | 1 | 2002 | 25 | 0.050 |
Why?
| Metaplasia | 2 | 2018 | 56 | 0.050 |
Why?
| Pulmonary Fibrosis | 2 | 1998 | 304 | 0.050 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2005 | 512 | 0.050 |
Why?
| Sex Factors | 1 | 2007 | 1758 | 0.050 |
Why?
| Radiation Dosage | 1 | 2002 | 143 | 0.050 |
Why?
| Hospitals, Veterans | 1 | 2002 | 239 | 0.050 |
Why?
| Reproducibility of Results | 1 | 2008 | 2818 | 0.050 |
Why?
| Cohort Studies | 4 | 2015 | 5050 | 0.040 |
Why?
| Gene Expression Regulation | 1 | 1989 | 2408 | 0.040 |
Why?
| Feasibility Studies | 1 | 2002 | 750 | 0.040 |
Why?
| Amino Acid Sequence | 3 | 1994 | 2032 | 0.040 |
Why?
| Gastrin-Releasing Peptide | 2 | 1996 | 6 | 0.040 |
Why?
| Signal Transduction | 3 | 1998 | 4606 | 0.040 |
Why?
| Light | 1 | 2001 | 335 | 0.040 |
Why?
| Autocrine Communication | 1 | 1998 | 42 | 0.040 |
Why?
| gamma Catenin | 1 | 2018 | 17 | 0.040 |
Why?
| Desmoglein 3 | 1 | 2018 | 17 | 0.040 |
Why?
| Loss of Heterozygosity | 2 | 2013 | 40 | 0.040 |
Why?
| Paracrine Communication | 1 | 1998 | 55 | 0.040 |
Why?
| Bronchial Diseases | 1 | 2018 | 34 | 0.040 |
Why?
| DNA Primers | 2 | 1998 | 525 | 0.040 |
Why?
| Up-Regulation | 2 | 2005 | 837 | 0.040 |
Why?
| Gene Expression Profiling | 1 | 2005 | 1588 | 0.040 |
Why?
| Neoplasm Transplantation | 1 | 1998 | 242 | 0.040 |
Why?
| Cell Cycle Checkpoints | 1 | 2018 | 85 | 0.040 |
Why?
| Time | 1 | 2018 | 75 | 0.040 |
Why?
| Vascular Cell Adhesion Molecule-1 | 1 | 1998 | 37 | 0.040 |
Why?
| Telangiectasia, Hereditary Hemorrhagic | 1 | 1998 | 10 | 0.040 |
Why?
| United States | 2 | 2011 | 12379 | 0.040 |
Why?
| Polymorphism, Single-Stranded Conformational | 1 | 1997 | 28 | 0.040 |
Why?
| Genes, Tumor Suppressor | 1 | 1998 | 76 | 0.040 |
Why?
| Alveolitis, Extrinsic Allergic | 1 | 1998 | 84 | 0.040 |
Why?
| Likelihood Functions | 1 | 1998 | 134 | 0.040 |
Why?
| Polymorphism, Restriction Fragment Length | 1 | 1997 | 64 | 0.040 |
Why?
| Neoplasm Staging | 2 | 2012 | 1206 | 0.040 |
Why?
| DNA, Complementary | 1 | 1998 | 263 | 0.040 |
Why?
| Codon | 1 | 1997 | 84 | 0.040 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 1998 | 280 | 0.040 |
Why?
| Introns | 1 | 1998 | 228 | 0.040 |
Why?
| Treatment Outcome | 1 | 2011 | 9256 | 0.040 |
Why?
| Membrane Glycoproteins | 1 | 1999 | 439 | 0.040 |
Why?
| Mice, Nude | 1 | 1998 | 653 | 0.040 |
Why?
| Incidence | 3 | 2010 | 2377 | 0.040 |
Why?
| Machine Learning | 1 | 2020 | 315 | 0.040 |
Why?
| Immunoassay | 2 | 1998 | 99 | 0.030 |
Why?
| Enzyme Activation | 1 | 1998 | 793 | 0.030 |
Why?
| RNA, Neoplasm | 1 | 1996 | 76 | 0.030 |
Why?
| Image Processing, Computer-Assisted | 1 | 2020 | 696 | 0.030 |
Why?
| Mesothelioma | 1 | 1996 | 31 | 0.030 |
Why?
| Glycopeptides | 1 | 1996 | 58 | 0.030 |
Why?
| Antigens, CD | 2 | 1998 | 450 | 0.030 |
Why?
| Databases, Factual | 1 | 2020 | 1167 | 0.030 |
Why?
| Sequence Analysis, DNA | 1 | 1998 | 741 | 0.030 |
Why?
| Proto-Oncogene Proteins | 1 | 2018 | 615 | 0.030 |
Why?
| Myelin Sheath | 1 | 1996 | 146 | 0.030 |
Why?
| Cell Cycle Proteins | 1 | 2018 | 563 | 0.030 |
Why?
| Prospective Studies | 3 | 2012 | 6389 | 0.030 |
Why?
| Receptors, Peptide | 1 | 1994 | 18 | 0.030 |
Why?
| Rh-Hr Blood-Group System | 1 | 1994 | 11 | 0.030 |
Why?
| Liver Neoplasms | 1 | 1998 | 523 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 1996 | 534 | 0.030 |
Why?
| Blotting, Southern | 1 | 1993 | 66 | 0.030 |
Why?
| Erythrocyte Membrane | 1 | 1994 | 53 | 0.030 |
Why?
| Blotting, Northern | 1 | 1993 | 190 | 0.030 |
Why?
| Endoscopy | 1 | 2015 | 266 | 0.030 |
Why?
| DNA, Neoplasm | 1 | 1993 | 151 | 0.030 |
Why?
| Solid Phase Microextraction | 1 | 2012 | 8 | 0.030 |
Why?
| Colorado | 1 | 2002 | 4120 | 0.030 |
Why?
| Cells, Cultured | 2 | 2007 | 3956 | 0.030 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1158 | 0.030 |
Why?
| Dinoprostone | 2 | 2004 | 191 | 0.030 |
Why?
| Fluorescent Antibody Technique | 1 | 1993 | 400 | 0.030 |
Why?
| Breath Tests | 1 | 2012 | 88 | 0.030 |
Why?
| Enzyme Inhibitors | 1 | 1996 | 775 | 0.030 |
Why?
| Gas Chromatography-Mass Spectrometry | 1 | 2012 | 129 | 0.030 |
Why?
| Cloning, Molecular | 1 | 1993 | 524 | 0.030 |
Why?
| Iceland | 1 | 2011 | 6 | 0.020 |
Why?
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2011 | 12 | 0.020 |
Why?
| Spain | 1 | 2011 | 34 | 0.020 |
Why?
| Respiratory Tract Diseases | 1 | 1992 | 141 | 0.020 |
Why?
| Netherlands | 1 | 2011 | 65 | 0.020 |
Why?
| Rats, Sprague-Dawley | 1 | 1996 | 2321 | 0.020 |
Why?
| Cattle | 1 | 1993 | 957 | 0.020 |
Why?
| Administration, Oral | 1 | 2012 | 744 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2018 | 2633 | 0.020 |
Why?
| Meta-Analysis as Topic | 1 | 2011 | 165 | 0.020 |
Why?
| Prognosis | 2 | 2012 | 3390 | 0.020 |
Why?
| Flow Cytometry | 1 | 1993 | 1063 | 0.020 |
Why?
| Carrier Proteins | 1 | 1994 | 719 | 0.020 |
Why?
| Receptor, IGF Type 1 | 1 | 2009 | 59 | 0.020 |
Why?
| Area Under Curve | 1 | 2010 | 285 | 0.020 |
Why?
| Cystic Fibrosis | 1 | 1998 | 977 | 0.020 |
Why?
| International Agencies | 1 | 2009 | 29 | 0.020 |
Why?
| Erythrocytes | 1 | 1994 | 604 | 0.020 |
Why?
| Pilot Projects | 1 | 2012 | 1394 | 0.020 |
Why?
| Chromatography, High Pressure Liquid | 1 | 1989 | 475 | 0.020 |
Why?
| Mass Spectrometry | 1 | 2010 | 661 | 0.020 |
Why?
| Genome, Human | 1 | 2009 | 377 | 0.020 |
Why?
| Models, Statistical | 1 | 2010 | 627 | 0.020 |
Why?
| Disease Models, Animal | 1 | 1996 | 3648 | 0.020 |
Why?
| Amino Acids | 1 | 1989 | 460 | 0.020 |
Why?
| Genotype | 1 | 2011 | 1854 | 0.020 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2005 | 102 | 0.020 |
Why?
| Genomics | 1 | 2009 | 658 | 0.020 |
Why?
| Epoprostenol | 1 | 2004 | 132 | 0.010 |
Why?
| Bronchiolitis | 1 | 2004 | 82 | 0.010 |
Why?
| Autoantibodies | 1 | 2010 | 1332 | 0.010 |
Why?
| Pituitary Neoplasms | 1 | 2004 | 161 | 0.010 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 965 | 0.010 |
Why?
| Vegetables | 1 | 2003 | 131 | 0.010 |
Why?
| Fruit | 1 | 2003 | 129 | 0.010 |
Why?
| Respiratory Function Tests | 1 | 2004 | 523 | 0.010 |
Why?
| Adenoma | 1 | 2004 | 190 | 0.010 |
Why?
| Genetic Predisposition to Disease | 1 | 2011 | 2227 | 0.010 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 761 | 0.010 |
Why?
| Weight Gain | 1 | 2004 | 481 | 0.010 |
Why?
| Regression Analysis | 1 | 2003 | 971 | 0.010 |
Why?
| Single-Blind Method | 1 | 2001 | 259 | 0.010 |
Why?
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2000 | 54 | 0.010 |
Why?
| Carcinoma | 1 | 2001 | 201 | 0.010 |
Why?
| RNA | 1 | 2005 | 827 | 0.010 |
Why?
| Bronchoscopes | 1 | 1998 | 5 | 0.010 |
Why?
| Retrospective Studies | 1 | 2015 | 12823 | 0.010 |
Why?
| Endoglin | 1 | 1998 | 20 | 0.010 |
Why?
| Random Allocation | 1 | 1998 | 339 | 0.010 |
Why?
| Reference Values | 1 | 1998 | 750 | 0.010 |
Why?
| Genetic Linkage | 1 | 1998 | 311 | 0.010 |
Why?
| Longitudinal Studies | 1 | 2003 | 2480 | 0.010 |
Why?
| Comorbidity | 1 | 2001 | 1487 | 0.010 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2000 | 450 | 0.010 |
Why?
| Diet | 1 | 2003 | 1128 | 0.010 |
Why?
| Linear Models | 1 | 1998 | 802 | 0.010 |
Why?
| Receptors, Cell Surface | 1 | 1998 | 355 | 0.010 |
Why?
| Analysis of Variance | 1 | 1998 | 1239 | 0.010 |
Why?
| Young Adult | 1 | 2011 | 10674 | 0.010 |
Why?
| Alleles | 1 | 1998 | 816 | 0.010 |
Why?
| Infant, Premature | 1 | 1998 | 478 | 0.010 |
Why?
| Risk Assessment | 1 | 2004 | 3021 | 0.010 |
Why?
| CD47 Antigen | 1 | 1994 | 22 | 0.010 |
Why?
| Chromatography, Affinity | 1 | 1994 | 84 | 0.010 |
Why?
| Endothelium, Vascular | 1 | 2000 | 860 | 0.010 |
Why?
| Moths | 1 | 1994 | 36 | 0.010 |
Why?
| Genes | 1 | 1994 | 221 | 0.010 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 1994 | 322 | 0.010 |
Why?
| Cytoplasm | 1 | 1994 | 269 | 0.010 |
Why?
| Chromosome Mapping | 1 | 1994 | 498 | 0.010 |
Why?
| Carcinoid Tumor | 1 | 1992 | 25 | 0.010 |
Why?
| Adolescent | 1 | 2011 | 18213 | 0.010 |
Why?
| Lymphocytes | 1 | 1994 | 340 | 0.010 |
Why?
| Transfection | 1 | 1994 | 877 | 0.010 |
Why?
| Dyspnea | 1 | 1992 | 202 | 0.010 |
Why?
| Mice, Inbred BALB C | 1 | 1994 | 1183 | 0.010 |
Why?
| Binding Sites | 1 | 1994 | 1206 | 0.010 |
Why?
| Fibrosis | 1 | 1992 | 478 | 0.010 |
Why?
| Phenotype | 1 | 1998 | 2891 | 0.010 |
Why?
| Aging | 1 | 1998 | 1653 | 0.010 |
Why?
| Infant, Newborn | 1 | 1998 | 5170 | 0.000 |
Why?
| Infant | 1 | 1998 | 8121 | 0.000 |
Why?
| Child, Preschool | 1 | 1998 | 9322 | 0.000 |
Why?
| Child | 1 | 1998 | 18876 | 0.000 |
Why?
|
|
Miller's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|